Core Insights - The report highlights the successful implementation of a colorectal cancer screening program in Yangzhou's Hanjiang District, which provided free screenings to approximately 200,000 residents aged 40-74 from 2021 to 2023, detecting 120 cases of colorectal cancer, 1,942 precancerous adenomas, and 859 polyps, thus establishing an effective screening pathway suitable for grassroots healthcare in China [1][2] Group 1: Screening Program Overview - The program covered 15 towns and 146 villages, collaborating with local hospitals to ensure timely diagnosis and treatment for positive screening results, enhancing participation in screenings and providing a practical model for the large-scale application of early screening technologies [2] - The project utilized Kunyan Biotech's blood multi-gene methylation technology for initial screening, followed by colonoscopy for confirmation, creating an integrated service loop from prevention to follow-up [1][2] Group 2: Industry Context and Future Implications - With colorectal cancer incidence and mortality rates rising in China, the early screening industry is experiencing a convergence of policy, technology, and market opportunities, with approximately 520,000 new cases and 240,000 deaths reported in 2022 [1] - The success of the Hanjiang project serves as a sustainable and replicable model for chronic disease management in China, paving the way for the release of the "Expert Consensus on Colorectal Cancer Screening for Community Residents" in April 2024, which will provide technical standards and practical guidelines for nationwide screening efforts [2]

Group 1 - The report on the colorectal cancer screening project in Yangzhou's Hanjiang District highlights the successful implementation of a non-invasive blood-based multi-gene methylation detection technology, screening approximately 200,000 residents aged 40 to 74 from 2021 to 2023, detecting 120 cases of colorectal cancer and 1,942 cases of precancerous adenomas [1] - The annual incidence of colorectal cancer in China is about 520,000 cases, with approximately 240,000 deaths, indicating a severe prevention and control situation [1] - Traditional colonoscopy is challenging for large-scale population screening due to its invasive nature, complexity, and uneven distribution of medical resources [1] Group 2 - The project has established a dual-stage screening path of "molecular initial screening + colonoscopy confirmation," which enhances screening compliance and alleviates medical resource pressure, providing a replicable and sustainable prevention model for addressing the high incidence of colorectal cancer in China [1] - The project is recognized as a "demonstration model that is feasible, sustainable, and promotable" for major chronic disease prevention in China, as stated by a Chinese Academy of Engineering academician [2] - The integration of molecular diagnostics into the colorectal cancer screening, diagnosis, treatment, and management loop is gradually being replicated in various regions across the country, with the potential to expand to other high-incidence cancers such as gastric and liver cancer, creating a larger early screening market [2]